|
|
 |
|
Viewing report
|
|
|
|
Atrial Fibrillation: Emerging Drug Discovery Targets and Therapeutic Candidates
Lead Discovery, May 2006, Pages: 69
The commonly quoted figure describing the number of Americans with atrial fibrillation is about 2.2 million. The current prevalence is now considerably larger than this and is set to continue growing. The condition is a risk factor for stroke and patients with atrial fibrillation tend to suffer more severely from strokes than the general population.
Treatment options are currently sub-optimal largely depending on the use of rate controlling agents and anticoagulants. The use of rate control agents rather than antiarrhythmics stems from 5 major clinical trials demonstrating that rate control is as effective as rhythm control an associated with fewer adverse effect. This however is largely a reflection of the need to develop next generation antiarrhythmics.
The global antiarrhythmic market is set to enter a period of revival reaching $3.5 billion by 2015. This resurgence is being led by Cardiome's RSD1235 which is expected to enter the market imminently and predicted to command 27% of the whole market by 2015. The blockbuster potential of RSD1235 and the relatively empty late stage pipeline for antiarrhythmic should represent a powerful driver for companies in the cardiovascular or ion channel arena to develop new candidates.
Atrial Fibrillation: Emerging drug discovery targets and therapeutic candidates is a state of the art report produced for all in the drug development sector. The report offers a detailed look at the biology of cardiac rhythm; the etiology and current treatment of arrhythmias and a proof of concept study to identify molecular targets for next generation antiarrhythmics. The report fully evaluates pipeline candidates for the treatment of atrial fibrillation and discusses future pharmacological approaches in the context of interventional strategies such as catheter ablation and surgical approaches.
The report also provides a detailed look at the related condition: ventricular fibrillation.
|
|
|
|
